Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITI-3000 in polyomavirus-positive Merkel cell carcinoma
NCT05422781Phase 1Completed
- Sponsor
- Immunomic Therapeutics, Inc.
- Start
- Jun 2022
- Primary completion
- Jun 2023
- Modality
- Prophylactic Vaccines, DNA Vaccines, Cancer Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ITI-3000 in Merkel cell carcinoma (MCC), sponsored by Immunomic Therapeutics, Inc. Primary endpoints: Number of participants with Dose Limiting Toxicities at 12 months, Number of occurrences of Adverse events/Serious Adverse Events at 12 months and 5 more. Started Jun 2022; status: completed.
02
Drugs
ITI-3000
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT05422781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05422781.